Related Experiment Videos
A role for interleukin-1 alpha in immunologically mediated intestinal pathology
A M Mowat1, A K Hutton, P Garside
1Department of Immunology, University of Glasgow, Western Infirmary, U.K.
Immunology
|September 1, 1993
Summary
Interleukin-1 (IL-1) drives inflammation in graft-versus-host disease (GVHD) enteropathy. Blocking IL-1 reduces intestinal damage, suggesting a key role for this cytokine in GVHD-related gut pathology.
Area of Science:
- Immunology
- Gastroenterology
- Pathology
Background:
- Interleukin-1 (IL-1) is a key mediator of inflammation.
- IL-1 is implicated in various immunopathological conditions.
- The role of IL-1 in graft-versus-host disease (GVHD) enteropathy is not well understood.
Purpose of the Study:
- To investigate the role of IL-1 in the development of enteropathy during GVHR in mice.
- To determine if IL-1 contributes to the intestinal pathology observed in GVHR.
Main Methods:
- Utilized a mouse model of GVHR.
- Administered rabbit anti-IL-1 alpha antibodies to mice with GVHR.
- Assessed intestinal morphology (crypt hyperplasia, crypt length, villus atrophy) and immune cell infiltration (intraepithelial lymphocytes).
- Administered recombinant IL-1 to normal mice and stimulated intestinal epithelial cells in vitro.
Main Results:
- Mice with GVHR exhibited increased IL-1 production.
- Anti-IL-1 alpha antibody treatment prevented crypt hyperplasia and reduced crypt length in the jejunum.
- Antibody treatment did not affect intraepithelial lymphocyte counts or splenomegaly.
- Recombinant IL-1 induced villus atrophy, crypt hyperplasia, and increased intraepithelial lymphocytes in normal mice.
- IL-1 stimulated intestinal epithelial cell proliferation in vitro.
Conclusions:
- IL-1 plays a significant effector role in immunologically mediated enteropathy during GVHR.
- IL-1 may exert its effects directly on intestinal epithelial cells or indirectly via stromal cells.
- Targeting IL-1 could be a therapeutic strategy for GVHD-related enteropathy.